Independent report confirms Ambience Healthcare’s AI platform reduces clinician burnout, enhances patient care, and ...

Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a ...

An often cited example of the importance of including a wide sample of patients is research showing that certain drugs can be ...

Generative AI and large language models (LLMs) are transforming how we interact with data across numerous domains. In healthcare, these models demonstrate ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

Subjects visit the study site every 21 days (±3 days) at which time safety monitoring – including for adverse events (AEs), as well as a physical examination, laboratory evaluations (clinical ...

"This year's report reveals a number of very encouraging developments in Alzheimer's research, including significantly more Phase I clinical trials and several additional drugs that have shown ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis ... This March, Novartis reported positive efficacy and safety outcomes from the Phase III ...

The ENLIGHTEN program consists of two Phase 3 clinical trials, ENLIGHTEN 1 and ENLIGHTEN 2, to evaluate the efficacy and safety of LYR-210 for the treatment of CRS. While the ENLIGHTEN 2 trial met ...